April 12, 2018 HOUSTON–(BUSINESS WIRE)–SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc nucleus using Human Dermal Fibroblasts, has filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) to expand its study of CybroCell Human Dermal Fibroblasts to treat degenerative disc disease.“The filing of […]